About Us
Clinical trial results showed an average weight loss of
20.9%
Product Details
The results of the SURMOUNT-1 clinical study of tepoxetine were published in the authoritative journal "The New England Journal of Medicine". Tirzepatide can help patients lose weight continuously throughout the treatment period. At the end of the 72-week treatment period, the average weight loss of adults receiving a 15mg dose was 20.9%.
Reduce fat mass more effectively
Using Tirzepatide: 75% of the weight loss comes from fat mass and 25% from fat-free mass, which is significantly more effective. Compared with the previous generation of products, 61% of the weight loss comes from fat mass and 39% from fat-free mass.
Product Details
The world's only dual-target agonist obesity treatment drug
Product Details
Promo Code
Invite Affiliate Members